Clinical Trials
23 trialsNCT07598110 2026-05-20
FT-RIC-HAPLO
Institut Paoli-Calmettes
Phase 2 Not yet recruiting
NCT07493538 2026-04-16
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT04965597 2026-03-09
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT04195633 2026-02-27
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT04994808 2026-01-26
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 2 Active not recruiting
NCT07232953 2025-11-18
FT14
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Active not recruiting
NCT07025824 2025-09-03
RELEVANT
Technische Universität Dresden
Phase 2 Not yet recruiting
NCT05636787 2024-07-08
TreoMel
Insel Gruppe AG, University Hospital Bern
Phase 2 Recruiting
NCT03961919 2023-11-18
FLAT-Auto
IRCCS San Raffaele
Phase 2 Completed
NCT00796068 2023-02-17
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00860574 2021-06-22
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01894477 2021-06-03
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 2 Unknown
NCT02333058 2020-05-04
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
medac GmbH
Phase 2 Completed
NCT02852083 2018-01-18
ModuLung
University Hospital Regensburg
Phase 2 Unknown
NCT00427999 2016-11-21
INV342
Novartis
Phase 2 Completed
NCT01772953 2016-10-12
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
Center for International Blood and Marrow Transplant Research
Phase 2 Completed
NCT01079013 2016-04-20
Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
Sheba Medical Center
Phase 2 Unknown
NCT00491634 2015-12-02
Treosulfan-based Conditioning for Transplantation in AML/MDS
Sheba Medical Center
Phase 2 Completed
NCT01810926 2013-03-14
T&B Depletion Non Malignant
Bambino Gesù Hospital and Research Institute
Phase 2 Unknown
NCT01063660 2010-02-05
Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)
medac GmbH
Phase 2 Completed
NCT01062490 2010-02-04
Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)
medac GmbH
Phase 2 Completed
NCT00129155 2007-10-04
MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
Hospices Civils de Lyon
Phase 2 Unknown
NCT00168870 2007-08-31
Study of Metastatic Ocular Melanoma
Charite University, Berlin, Germany
Phase 2 Unknown